logo
  • Home
  • About
  • Team
  • Partner Opportunities
  • Product Development
  • News
  • Contact
  • Home
  • About
  • Team
  • Partner Opportunities
  • Product Development
  • News
  • Contact
  • Developing First-in-Class
    Dual Inhibitors Targeting
    Both BET Bromodomains and
    Dopamine Receptor 2 for the
    Treatment of Rare Diseases
  © 2017 ConverGene LLC, All Rights Reserved.